Rheumatoid Arthritis

What is Rheumatoid Arthritis?

Rheumatoid Arthritis (RA) is a chronic, systemic inflammatory autoimmune disease that primarily targets the synovial joints — the lining of the membranes surrounding your joints. Unlike osteoarthritis, which is caused by mechanical wear-and-tear, RA is driven by a misdirected immune response. The body's own immune cells, particularly T-cells and B-cells, infiltrate the synovium, triggering persistent inflammation that, if left unchecked, can erode cartilage and bone, leading to permanent joint deformity and disability.

What makes RA particularly insidious is that it is a systemic disease — it does not confine itself to the joints. In many patients, RA also causes inflammation in the lungs (pleural effusion, interstitial lung disease), the heart (pericarditis), the eyes (scleritis, episcleritis), and the blood vessels (rheumatoid vasculitis). Understanding and managing these extra-articular manifestations is a critical component of comprehensive RA care.

Characteristic symmetrical joint swelling in Rheumatoid Arthritis, most commonly affecting hands and wrists.

Who Gets Rheumatoid Arthritis?

RA affects approximately 1% of the global population, making it the most common inflammatory arthritis. It predominantly affects women (2-3 times more than men) and typically presents between the ages of 30 and 60, although it can occur at any age. Several risk factors have been identified:

• Genetics: Individuals carrying the HLA-DRB1 gene (the "shared epitope") have a significantly elevated risk of developing RA and tend to have more severe disease.
• Smoking: One of the strongest modifiable risk factors. Smoking activates immune cells and triggers the production of anti-CCP antibodies, especially in genetically susceptible individuals.
• Hormonal Factors: The higher prevalence in women and the known influence of pregnancy (often inducing remission) and the post-partum period (often triggering flares) underscore the role of sex hormones.
• Environmental Triggers: Periodontal disease, gut microbiome dysbiosis, and certain infections have been proposed as environmental triggers that initiate the autoimmune cascade in predisposed individuals.

Recognizing the Symptoms

The hallmark of RA is symmetrical, inflammatory joint pain — both wrists, both knuckle joints (MCPs and PIPs), both knees are affected simultaneously. This symmetry is a key differentiating feature from many other forms of arthritis.

• Morning Stiffness lasting >1 hour: This is a defining feature of inflammatory arthritis. The stiffness that persists well into the morning is a critical clue.
• Tender, Warm, Swollen Joints: Joints feel puffy, are warm to touch, and are acutely tender even to light pressure.
• Fatigue and Malaise: Profound, debilitating fatigue — often described as a "flu-like" exhaustion — is a major and frequently underappreciated symptom.
• Rheumatoid Nodules: Firm lumps under the skin, especially over bony prominences like elbows, seen in seropositive RA.
• Fever and Weight Loss: Low-grade fevers and unintended weight loss are common in active, systemic disease.

X-ray imaging showing periarticular osteopenia and early erosive changes — findings typical of progressive RA.

Advanced Diagnostic Evaluation

Diagnosing RA requires a meticulous approach, combining clinical assessment with targeted laboratory and imaging investigations:

• Anti-CCP Antibodies (ACPA): The most specific blood test for RA (95% specificity). Anti-CCP can be positive years before clinical symptoms appear, and is a marker of more erosive, aggressive disease.
• Rheumatoid Factor (RF): Positive in 70-80% of RA patients. However, it can be positive in many other conditions, so it must be interpreted alongside clinical findings.
• Inflammatory Markers — ESR & CRP: Elevated, reflecting systemic inflammation. Used to monitor disease activity and treatment response.
• Musculoskeletal Ultrasound: A game-changer in early RA diagnosis. It detects synovial thickening, increased blood flow (power Doppler), and early erosions that are invisible on X-rays, allowing much earlier treatment initiation.
• MRI of hands/feet: Most sensitive modality for detecting bone marrow edema and early erosions.
• X-rays (baseline): Essential for documenting the degree of joint damage and monitoring disease progression over time.

Treatment: A Modern Era of Targeted Therapy

The last 25 years have witnessed a revolution in RA management, with effective treatments now enabling the majority of patients to achieve sustained remission — something that was unthinkable two decades ago. The core principle is "Treat to Target" — setting a specific goal (remission or low disease activity) and adjusting treatment aggressively until that target is reached.

Conventional Synthetic DMARDs (csDMARDs)

Methotrexate remains the cornerstone of RA treatment — the "anchor drug." It is safe, effective, and inexpensive when monitored appropriately. It is often combined with Hydroxychloroquine and Sulfasalazine (triple therapy) for enhanced efficacy. Leflunomide is an important alternative for patients who cannot tolerate Methotrexate.

Biologic DMARDs (bDMARDs)

When conventional DMARDs are insufficient, powerful biological therapies are added. These precision medicines target specific molecules in the inflammatory pathway:

• TNF Inhibitors (Etanercept, Adalimumab, Infliximab) — the most commonly used biologics.
• IL-6 Inhibitors (Tocilizumab, Sarilumab) — particularly effective for fatigue and systemic manifestations.
• CD20 inhibitors (Rituximab) — a B-cell depleting therapy useful in seropositive RA.
• CTLA-4-Ig (Abatacept) — targets T-cell co-stimulation.

Targeted Synthetic DMARDs (JAK Inhibitors)

Oral JAK inhibitors (Tofacitinib, Baricitinib, Upadacitinib) are a newer class of highly effective oral medications that block intracellular signaling pathways. They offer the convenience of a pill with biologic-level efficacy.